Drug combo plus radiation for liver cancer after first treatment
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two drugs (benmelstobart and anlotinib) plus a precise form of radiation (SBRT) for people with liver cancer that has spread a little and has already stopped responding to first-line treatment. The goal is to see if this combination can help control the cancer better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old and have liver cancer (hepatocellular carcinoma) that cannot be removed with surgery.
- You must have already tried a first-line treatment that included a targeted therapy and an immunotherapy, and it stopped working.
- Your cancer must have spread to only a few spots (no more than 5 total, in no more than 2 organs), and these spots must be treatable with SBRT (a precise type of radiation).
- Your liver and kidney function need to be good enough, and your blood counts must meet certain minimums.
- You must be able to care for yourself (ECOG 0-1) and expected to live at least 3 more months.
- You must not have had certain heart conditions, active infections, or a history of interstitial lung disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of focused radiation (SBRT), an immunotherapy drug (adelimumab), and a targeted therapy pill (apatinib) for liver cancer that can be removed with surgery. The goal is to see if this combination can shrink tumors before surgery and help prevent the cancer from coming back.
This trial tests a combination of two immunotherapy drugs (ipilimumab and nivolumab) plus targeted radiation (SBRT) for people with liver cancer that is advanced but has not spread outside the liver. The goal is to see if this approach can shrink tumors and make them easier to remove with surgery.
This study tests a combination of two drugs (anlotinib and benmelstobart) with a liver-directed chemotherapy procedure (HAIC) in people with liver cancer that cannot be removed surgically. The goal is to see if this combo shrinks tumors and is safe.
This trial tests a combination of radiation (SBRT), an immunotherapy drug (PD-L1 inhibitor), and a targeted therapy (lenvatinib) for people with liver cancer that has spread to abdominal lymph nodes. It may be an option if you haven't taken certain immunotherapies before or if your cancer progressed after them.
This trial tests a combination of three treatments—radiation therapy (SBRT), an immunotherapy drug (camrelizumab), and a targeted therapy (apatinib)—to see if they can shrink liver cancer enough to make surgery possible. It is for people whose liver cancer cannot be removed right now.
This trial tests a combination of targeted radiation (SBRT) and immunotherapy for people with small liver cancers that have come back or are still present after prior treatment. It aims to see if this approach can better control the cancer without using heavy chemotherapy.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.